Cell fractions containing cells capable of differentiating into neural cells

• US 20040121461A1
• Filed: 12/23/2002
• Published: 06/24/2004
• Est. Priority Date: 06/26/2000
• Status: Active Grant

• Current Assignee: NC Medical Research Inc. (e-solutions, Inc. /Japan/), Mitsui Sumitomo Insurance Care Network Co., Ltd. (Ms&Ad Insurance Group Holdings Incorporated)
• Original Assignee: Renomedix Institute, Inc.
• Inventors: Honmou, Osamu, Hashi, Kazuo, Uede, Teiji
• Granted Patent: US 7,098,027 B2
• Time in Patent Office: Days
• US Class Current: 435/368
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2506/1353 from bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0622 Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
• CPC Class Codes: C12N 5/0662 Stem cells
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0664 Dental pulp stem cells, Dental follicle stem cells
• CPC Class Codes: C12N 5/0665 Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: C12N 5/0666 Mesenchymal stem cells from hair follicles
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/0668 : Mesenchymal stem cells from other natural sources
• CPC Class Codes: C12N 5/0676 : Pancreatic cells

Abstract

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

Claims

1. A mononuclear cell fraction containing cells capable of differentiating into neural cells, wherein said fraction is isolated from bone marrow cells or cord blood cells collected from vertebrate.

2. The cell fraction according to claim 1, which can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml.

4. The cell fraction according to claim 3, which can be prepared by recovering cells having the character SH2(+), SH3(+), SH4 (+), CD29 (+), CD44 (+), CD14 (−

), CD34(−

), and CD45(−

), from the cell fraction according to claim 2.

7. The cell fraction according to claim 6, which can be prepared by recovering cells having the character Lin(−

), Sca-1(+), CD10(+) CD11D (+), CD44 (+), CD45 (+), CD71 (+), CD90 (+), CD105 (+), CDW123 (+) CD127(+), CD164(+) fibronectin (+), ALPH(+), and collagenase-1(+) from the cell fraction according to claim 2.

11. A cell capable of differentiating into neural cells, which is contained in the cell fraction according to any one of claims 1 to 10.

12. A composition for treating neurological diseases, which comprises the cell fraction according to any one of claims 1 to 10, or the cell according to claim 11.

13. The composition according to claim 12, wherein the neurological disease is selected from the group consisting of central and peripheral demyelinating diseases;

central and peripheral degenerative diseases;

cerebral apoplexy selected from cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage;

brain tumor;

dysfunction of higher function of the brain;

psychiatric diseases;

epilepsy;

traumatic neurological diseases;

infectious diseases; and

infarction of spinal cord.

14. A method for treating neurological diseases, which comprises transplanting, into a recipient, the cell fraction according to any one of claims 1 to 10, the cell according to claim 11, or the composition according to claim 12.

15. The therapeutic method according to claim 14, wherein the neurological disease is selected from the group consisting of central and peripheral demyelinating diseases;

central and peripheral degenerative diseases;

cerebral apoplexy selected from cerebral infarction, cerebral hemorrhage, and subarachnoid hemorrhage;

brain tumor;

dysfunction of higher function of the brain;

psychiatric diseases;

epilepsy;

traumatic neurological diseases;

infectious diseases; and

infarction of spinal cord.

16. The therapeutic method according to claim 15, wherein the cells to be transplanted are derived from the recipient.

3. A mononuclear cell fraction isolated from bone marrow cells of cord blood cells collected from vertebrate, wherein the fraction contains cells having the character SH2(+), SH3(+), SH4 (+), CD29(+) CD44(+), CD14(−

), CD34(−

), and CD45(−

), and are capable of differentiating into neural cells.

5. The cell fraction according to claim 3, which can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 900 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml.

6. A mononuclear cell fraction containing cells isolated from bone marrow cells or cord blood cells collected from vertebrate, wherein the fraction contains cells having the character Lin(−

) Sca-1 (+), CD10 (+), CD11D (+), CD44 (+), CD45 (+), CD71 (+), CD90 (+) CD105 (+), CDW123 (+) CD127 (+), CD164 (+), fibronectin (+), ALPH (+) and collagenase-1(+), and are capable of differentiating into neural cells.

8. The cell fraction according to claim 6, which can be prepared by subjecting bone marrow cells or cord blood cells collected from vertebrate to density-gradient centrifugation at 800 G in a solution for a sufficient time ensuring separation depending on specific gravity, and then recovering the cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml.

9. A mononuclear cell fraction isolated from bone marrow cells, cord blood cells, or embryonic hepatic tissues collected from vertebrate, wherein the fraction contains cells characterized by AC133(+), and are capable of differentiating into neural cells.

10. The cell fraction according to claim 9, which can be prepared by subjecting bone marrow cells, cord blood cells, or embryonic hepatic tissues collected from vertebrate to density-gradient centrifugation at 2,000 rpm in a solution for a sufficient time ensuring separation depending on specific gravity, recovering a cell fraction within the range of a specific gravity of 1.07 to 1.1 g/ml, and then recovering cells characterized by AC133(+) from the cell fraction.